Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on August 14, 2020, at 8:30 a.m. Eastern time, to discuss its second quarter 2020 financial results and provide a business update. CEO Cameron Reynolds, CFO David Vanston, and EVP of Investor Relations Scott Powell will discuss recent developments, ongoing clinical trials, and upcoming milestones. Investors can access the live call on Volition’s investor relations page, with a replay available until August 28, 2020. Volition specializes in blood tests for early disease diagnosis through its Nucleosomics technology.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its inclusion in the Russell 3000® and Russell Microcap® Indexes effective June 26, 2020. This recognition highlights the company's progress in developing cost-effective blood tests for cancer diagnosis. CEO Cameron Reynolds emphasized the potential for increased visibility and liquidity in shares following this index inclusion. The Russell Indexes represent approximately $9 trillion in assets, promoting further growth opportunities for Volition.